Azeria Therapeutics, a biotechnology company, raised £32m ($41m) in a Syncona-led series B funding round. "Azeria is the product of more than ten years of research by Professor Jason Carroll at Cancer Research UK's Cambridge Institute, University of Cambridge and was created to accelerate research and development into pioneer factors, a completely new target class in oncology including FOXA1. We would like to thank Sixth Element Capital for their continued support and look forward to working closely with Syncona to accelerate the development of breakthrough treatments for hormone resistant breast cancer patients," Stephen Myatt, Azeria Therapeutics Chief Executive Officer.